Suggestions
John Shields
Non Executive Director at Adaptate Biotherapeutics
John Shields is a highly experienced professional in the biopharmaceutical industry, currently serving as the Director of JGSbiopharma Ltd.12 With over 40 years of experience in the field, he has established himself as an expert in diagnostics devices and biotech.1
Professional Background
John Shields has held several significant positions throughout his career:
- Director at JGSbiopharma Ltd: His current role, where he provides scientific and technical advice to Abingworth and often serves as the first filter for investment proposals.1
- Senior Vice President of Research at Cantab Pharmaceuticals1
- Positions at the Glaxo Institute for Molecular Biology and the Institute of Child Health, UCL1
Advisory Roles and Committees
John Shields is actively involved in various advisory roles and committees:
- Expert in Residence at the Cambridge Academy of Therapeutic Sciences (CATS) at The University of Cambridge, focusing on Diagnostics and Medical Devices1
- Member of the Edinburgh BioQuarter Board
- Member of the MRC Translational Research Group committee
- Member of the BHF Translational Award Advisory Group
- Member of the Biomedical Catalyst Major Awards Committee
- Member of the Sanger Centre Translational Committee1
Education and Research
John Shields holds a PhD in Immunology from the University of Glasgow.1 He has made significant contributions to the scientific community, having published more than 30 papers in peer-reviewed journals, including Science.1
Industry Experience
Throughout his career, John has worked with various companies, ranging from startups to multinational corporations. Some of the notable organizations he has been associated with include:
- Sorex Sensors
- Smart Holograms
- Akubio
- Hypoguard
- Cambridge Consultants
- PA Consulting
- Genzyme
- Boehringer Mannheim1
His extensive experience spans across Europe and the United States, providing him with a broad perspective on managing technology startups, state-of-the-art operations, cross-functional teams, IP assets, and organizational expansion projects.1
